Details for Patent: 10,272,079
✉ Email this page to a colleague
Which drugs does patent 10,272,079 protect, and when does it expire?
Patent 10,272,079 protects XPHOZAH and is included in one NDA.
This patent has fifty patent family members in twenty-seven countries.
Summary for Patent: 10,272,079
| Title: | NHE3-binding compounds and methods for inhibiting phosphate transport |
| Abstract: | Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent. |
| Inventor(s): | Carreras Christopher, Charmot Dominique, Jacobs Jeffrey W, Labonte Eric, Lewis Jason G. |
| Assignee: | ARDELYX, INC. |
| Application Number: | US14783983 |
|
Patent Claim Types: see list of patent claims |
More… ↓ |
Drugs Protected by US Patent 10,272,079
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-001 | Oct 17, 2023 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERPHOSPHATEMIA | ⤷ Subscribe | ||||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-001 | Oct 17, 2023 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | REDUCTION OF SERUM PHOSPHORUS IN ADULTS | ⤷ Subscribe | ||||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-002 | Oct 17, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | REDUCTION OF SERUM PHOSPHORUS IN ADULTS | ⤷ Subscribe | ||||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-002 | Oct 17, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERPHOSPHATEMIA | ⤷ Subscribe | ||||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-003 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | REDUCTION OF SERUM PHOSPHORUS IN ADULTS | ⤷ Subscribe | ||||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-003 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERPHOSPHATEMIA | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,272,079
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 095852 | ⤷ Subscribe | |||
| Australia | 2014250956 | ⤷ Subscribe | |||
| Australia | 2019204676 | ⤷ Subscribe | |||
| Brazil | 112015025805 | ⤷ Subscribe | |||
| Canada | 2909169 | ⤷ Subscribe | |||
| China | 105392483 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
